Global Healthcare Industry – M&A and Capital Market Landscape Update
Evalueserve
DECEMBER 6, 2021
On the other hand, Biotech heavily underperformed post Q1’21 primarily due to the shifting of focus towards cyclicals and negative sentiments arising as of result of greater regulatory clampdown on transformative deals and drug pricing. Sponsor deals rebounded exceptionally.
98 
Let's personalize your content